Biogened S.A. (WSE:BGD)

Biogened Statistics

Total Valuation

Biogened has a market cap or net worth of PLN 58.46 million. The enterprise value is 82.02 million.

Market Cap	58.46M
Enterprise Value	82.02M

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	Sep 11, 2025

Share Statistics

Biogened has 2.46 million shares outstanding.

Current Share Class	2.46M
Shares Outstanding	2.46M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.17%
Float	144,714

Valuation Ratios

The trailing PE ratio is 10.02.

PE Ratio	10.02
Forward PE	n/a
PS Ratio	0.52
PB Ratio	1.33
P/TBV Ratio	1.35
P/FCF Ratio	67.65
P/OCF Ratio	15.76
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.97, with an EV/FCF ratio of 94.92.

EV / Earnings	14.06
EV / Sales	0.73
EV / EBITDA	5.97
EV / EBIT	8.63
EV / FCF	94.92

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.59.

Current Ratio	2.27
Quick Ratio	1.44
Debt / Equity	0.59
Debt / EBITDA	1.89
Debt / FCF	30.11
Interest Coverage	3.78

Financial Efficiency

Return on equity (ROE) is 14.05% and return on invested capital (ROIC) is 8.80%.

Return on Equity (ROE)	14.05%
Return on Assets (ROA)	6.52%
Return on Invested Capital (ROIC)	8.80%
Return on Capital Employed (ROCE)	14.11%
Revenue Per Employee	536,910
Profits Per Employee	27,770
Employee Count	227
Asset Turnover	1.24
Inventory Turnover	1.76

Taxes

In the past 12 months, Biogened has paid 1.88 million in taxes.

Income Tax	1.88M
Effective Tax Rate	24.35%

Stock Price Statistics

The stock price has decreased by -6.54% in the last 52 weeks. The beta is 0.18, so Biogened's price volatility has been lower than the market average.

Beta (5Y)	0.18
52-Week Price Change	-6.54%
50-Day Moving Average	26.17
200-Day Moving Average	25.10
Relative Strength Index (RSI)	39.26
Average Volume (20 Days)	58

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biogened had revenue of PLN 112.75 million and earned 5.83 million in profits. Earnings per share was 2.37.

Revenue	112.75M
Gross Profit	76.62M
Operating Income	9.50M
Pretax Income	7.71M
Net Income	5.83M
EBITDA	13.74M
EBIT	9.50M
Earnings Per Share (EPS)	2.37

Balance Sheet

The company has 2.46 million in cash and 26.02 million in debt, giving a net cash position of -23.56 million or -9.59 per share.

Cash & Cash Equivalents	2.46M
Total Debt	26.02M
Net Cash	-23.56M
Net Cash Per Share	-9.59
Equity (Book Value)	43.82M
Book Value Per Share	17.84
Working Capital	33.23M

Cash Flow

In the last 12 months, operating cash flow was 3.71 million and capital expenditures -2.85 million, giving a free cash flow of 864,100.

Operating Cash Flow	3.71M
Capital Expenditures	-2.85M
Free Cash Flow	864,100
FCF Per Share	0.35

Margins

Gross margin is 67.95%, with operating and profit margins of 8.43% and 5.17%.

Gross Margin	67.95%
Operating Margin	8.43%
Pretax Margin	6.84%
Profit Margin	5.17%
EBITDA Margin	12.19%
EBIT Margin	8.43%
FCF Margin	0.77%

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 2.02%.

Dividend Per Share	0.50
Dividend Yield	2.02%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	3
Payout Ratio	21.06%
Buyback Yield	n/a
Shareholder Yield	2.02%
Earnings Yield	9.98%
FCF Yield	1.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogened has an Altman Z-Score of 2.76 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.76
Piotroski F-Score	4